Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2026)

Revolution Medicines' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 112.64% year-over-year to -$453.8 million in Q1 2026; TTM through Mar 2026 was -$1.4 billion, a 96.66% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 billion, down 88.52% from the prior year.
• Net Income towards Common Stockholders retreated to -$453.8 million in Q1 2026 per RVMD's latest filing, from -$364.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$56.5 million in Q4 2022 and bottomed at -$453.8 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$133.2 million (2024), against an average of -$168.8 million.
• Across the five-year window, Net Income towards Common Stockholders slipped 7.31% in 2022 and sank 185.77% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$56.5 million in 2022, then sank by 185.77% to -$161.5 million in 2023, then slipped by 20.45% to -$194.6 million in 2024, then tumbled by 87.54% to -$364.9 million in 2025, then decreased by 24.37% to -$453.8 million in 2026.
• Per Business Quant, the three latest RVMD Net Income towards Common Stockholders figures stand at -$453.8 million (Q1 2026), -$364.9 million (Q4 2025), and -$305.2 million (Q3 2025).